Necroptosis-related LncRNAs in Skin Cutaneous Melanoma: Evaluating Prognosis, Predicting Immunity, and Guiding Therapy

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Aug 14

PMID 37580654

Authors

Jianlan Liu

Binlin Luo

Pengpeng Zhang

Keyu Jiang

Zuoqiong Hou

Xiaojian Cao

Jian Tang

Affiliations

Soon will be listed here.

Abstract

Background: An increasing amount of research has speculated that necroptosis could be a therapeutic strategy for treating cancer. However, understanding the prognostic value of the necroptosis-related long non-coding RNAs (NRLs) in skin cutaneous melanoma (SKCM, hereafter referred to as melanoma) remains poor and needs to be developed. Our research aims to construct a model based on NRLs for the prognosis of patients with melanoma.

Methods: We obtained the RNA-seq and clinical data from The Cancer Genome Atlas (TCGA) database and retrieved 86 necroptosis-related genes from the GeneCards database. The lncRNAs associated with necroptosis were identified via the Pearson correlation coefficient, and the prognostic model of melanoma was constructed using LASSO regression. Next, we employed multiple approaches to verify the accuracy of the model. Melanoma patients were categorized into two groups (high-risk and low-risk) according to the results of LASSO regression. The relationships between the risk score and survival status, clinicopathological correlation, functional enrichment, immune infiltration, somatic mutation, and drug sensitivity were further investigated. Finally, the functions of AL162457.2 on melanoma proliferation, invasion, and migration were validated by in vitro experiments.

Results: The prognostic model consists of seven NRLs (EBLN3P, AC093010.2, LINC01871, IRF2-DT, AL162457.2, AC242842.1, HLA-DQB1-AS1) and shows high diagnostic efficiency. Overall survival in the high-risk group was significantly lower than in the low-risk group, and risk scores could be used to predict melanoma survival outcomes independently. Significant differences were evident between risk groups regarding the expression of immune checkpoint genes, immune infiltration, immunotherapeutic response and drug sensitivity analysis. A series of functional cell assays indicated that silencing AL162457.2 significantly inhibited cell proliferation, invasion, and migration in A375 cells.

Conclusion: Our prognostic model can independently predict the survival of melanoma patients while providing a basis for the subsequent investigation of necroptosis in melanoma and a new perspective on the clinical diagnosis and treatment of melanoma.

Citing Articles

The role of multiomics in revealing the mechanism of skin repair and regeneration.

Shi S, Ou X, Long J, Lu X, Xu S, Li G Front Pharmacol. 2025; 16:1497988.

PMID: 39896077 PMC: 11782119. DOI: 10.3389/fphar.2025.1497988.

SILAC-based quantification reveals modulation of the immunopeptidome in BRAF and MEK inhibitor sensitive and resistant melanoma cells.

Bernhardt M, Rech A, Berthold M, Lappe M, Herbel J, Erhard F Front Immunol. 2025; 15():1490821.

PMID: 39835134 PMC: 11744270. DOI: 10.3389/fimmu.2024.1490821.

The Role of Non-coding RNAs in Tumorigenesis, Diagnosis/Prognosis, and Therapeutic Strategies for Cutaneous Melanoma.

Schaft N, Dorrie J Methods Mol Biol. 2024; 2883:79-107.

PMID: 39702705 DOI: 10.1007/978-1-0716-4290-0_4.

Numb and NumbL inhibit melanoma tumor growth by influencing the immune microenvironment.

Zhang S, Zang L, Li Y, Pang Y, Xin Y, Zhang Y BMC Cancer. 2024; 24(1):1419.

PMID: 39558287 PMC: 11571900. DOI: 10.1186/s12885-024-13191-9.

Construction of a tumor mutational burden-derived LncRNA prognostic computational framework associated with therapy sensitivity in skin cutaneous melanoma.

Li G, Wu T, Li H, Wei C, Sun Y, Gao P J Transl Med. 2024; 22(1):966.

PMID: 39449143 PMC: 11515383. DOI: 10.1186/s12967-024-05732-4.

References

Davis L, Shalin S, Tackett A . Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019; 20(11):1366-1379. PMC: 6804807. DOI: 10.1080/15384047.2019.1640032. View

Liu X, Xie X, Ren Y, Shao Z, Zhang N, Li L . The role of necroptosis in disease and treatment. MedComm (2020). 2022; 2(4):730-755. PMC: 8706757. DOI: 10.1002/mco2.108. View

Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J . Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020; 13(1):110. PMC: 7418434. DOI: 10.1186/s13045-020-00946-7. View

Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K . The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019; 18(1):100. PMC: 6532150. DOI: 10.1186/s12943-019-1029-8. View

Geserick P, Wang J, Schilling R, Horn S, Harris P, Bertin J . Absence of RIPK3 predicts necroptosis resistance in malignant melanoma. Cell Death Dis. 2015; 6:e1884. PMC: 4650439. DOI: 10.1038/cddis.2015.240. View

Khan M, Wellinger R, Laurent B . Exploring the Alternative Splicing of Long Noncoding RNAs. Trends Genet. 2021; 37(8):695-698. DOI: 10.1016/j.tig.2021.03.010. View

Reggiardo R, Maroli S, Kim D . LncRNA Biomarkers of Inflammation and Cancer. Adv Exp Med Biol. 2022; 1363:121-145. DOI: 10.1007/978-3-030-92034-0_7. View

He J, Zhu S, Liang X, Zhang Q, Luo X, Liu C . LncRNA as a multifunctional regulator in cancer multi-drug resistance. Mol Biol Rep. 2021; 48(8):1-15. DOI: 10.1007/s11033-021-06603-7. View

Zhang L, Liu C, Zhang X, Wang C, Liu D . Breast cancer prognosis and immunological characteristics are predicted using the m6A/m5C/m1A/m7G-related long noncoding RNA signature. Funct Integr Genomics. 2023; 23(2):117. DOI: 10.1007/s10142-023-01026-y. View

10.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

11.

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

12.

Hanzelmann S, Castelo R, Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. PMC: 3618321. DOI: 10.1186/1471-2105-14-7. View

13.

Kanehisa M, Goto S . KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999; 28(1):27-30. PMC: 102409. DOI: 10.1093/nar/28.1.27. View

14.

Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M . KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2022; 51(D1):D587-D592. PMC: 9825424. DOI: 10.1093/nar/gkac963. View

15.

Ruffo E, Wu R, Bruno T, Workman C, Vignali D . Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Semin Immunol. 2019; 42:101305. PMC: 6920665. DOI: 10.1016/j.smim.2019.101305. View

16.

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D . Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017; 18(1):248-262. DOI: 10.1016/j.celrep.2016.12.019. View

17.

Yoon J, Abdelmohsen K, Srikantan S, Yang X, Martindale J, De S . LincRNA-p21 suppresses target mRNA translation. Mol Cell. 2012; 47(4):648-55. PMC: 3509343. DOI: 10.1016/j.molcel.2012.06.027. View

18.

Strilic B, Yang L, Albarran-Juarez J, Wachsmuth L, Han K, Muller U . Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis. Nature. 2016; 536(7615):215-8. DOI: 10.1038/nature19076. View

19.

Rinn J, Chang H . Long Noncoding RNAs: Molecular Modalities to Organismal Functions. Annu Rev Biochem. 2020; 89:283-308. DOI: 10.1146/annurev-biochem-062917-012708. View

20.

Iyer M, Niknafs Y, Malik R, Singhal U, Sahu A, Hosono Y . The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015; 47(3):199-208. PMC: 4417758. DOI: 10.1038/ng.3192. View